Evidence

What your heart failure register is not telling you

Coding, registers and the four pillars in UK primary care

Semaglutide for secondary cardiovascular prevention: An update that may have gone unnoticed – what NICE TA1152 means for primary care

NICE TA1152 establishes semaglutide 2.4 mg as a secondary cardiovascular-prevention treatment for adults with established cardiovascular disease and a BMI of at least 27 kg/m². Niraj Lakhani considers what this means for primary care.

Finerenone may slow kidney decline in glomerular disease

A prespecified exploratory analysis of the FIND-CKD trial reports slower eGFR decline with finerenone in chronic kidney disease due to glomerular diseases.

Finerenone gets NICE backing for HFpEF and HFmrEF: what the final draft guidance means for primary care

NICE has published final draft guidance recommending finerenone (Kerendia) for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. With nearly 280,000 people in England potentially eligible, this is a significant moment for a patient group with few disease-modifying options.

Triglyceride-associated cardiovascular risk: Leaving risk on the table

Despite excellent LDL-cholesterol management, 1 in 3 patients with established ASCVD will experience a recurrent event within three years. Elevated triglycerides represent a major — yet frequently overlooked — driver of residual cardiovascular risk. Moudy Khodadi, Advanced Pharmacist Lipid Clinic, explains the mechanism, the evidence, and what actually works.

NG28 NICE GUIDELINES: The Flozin-First Era, and 810,000 More GLP-1 Patients

The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset.

Lipoprotein(a): The Overlooked Cardiovascular Risk Marker You Should Know About

Small Drop, Big Impact: Why Getting Blood Pressure to 120/80 Matters

Blood pressure management sits at the heart of cardiovascular prevention, yet many patients remain under-treated against optimal targets.

LDL Elevation in Menopause - Interpreting Lipids in Primary Care

From raised LDL to a new non-hormonal drug class and the largest HRT safety study to date, this week is all menopause in primary care.

SGLT2 trial watch

When a patient stops a medication, the assumption is usually that the benefits stop too. The EMPA-KIDNEY post-trial follow-up, published in NEJM, checked if this is true for SGLT2 inhibitors in CKD.

COBRRA delivers the first head-to-head DOAC comparison in VTE

For over a decade, the question of whether to use apixaban or rivaroxaban for treating acute VTE has remained. The COBRA Trial in NEJM finally provides a head-to-head comparison.

What could the future antihypertensive medication landscape look like?

Low-dose multi-drug pills are key and new ways to tackle resistant hypertension are emerging. Since 2022, many Phase III antihypertensive trials have been reported.

Statins past 80: what does the evidence actually say?

At what age do you stop offering statins for primary prevention? It's a question the guidelines can only partially answer.

The art of 'Diagnostic Elegance': refocusing the hypertension review

Recent evidence suggests that we are 'over-testing' our hypertension patients, says a report from BJGP.